机译:接受曲妥珠单抗化疗的HER2过表达转移性乳腺癌患者的脑转移
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Medical Oncology Division Hyogo Cancer Center Hyogo Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
Breast and Medical Oncology Division National Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan;
HER2-overexpressing breast cancer; Trastuzumab; Brain metastases;
机译:接受曲妥珠单抗化疗的HER2过表达转移性乳腺癌患者的脑转移。
机译:412 POSTER用曲妥珠单抗和化学疗法治疗的HER2过表达转移性乳腺癌(MBC)患者(pts)脑转移的高发生率
机译:单药拉帕替尼用于过度表达HER2的晚期或转移性乳腺癌,在一线或二线含曲妥珠单抗方案中进展。
机译:化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
机译:辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
机译:HER2mRNA的原位定量测量可预测一组转移性乳腺癌患者受益于曲妥珠单抗化疗。
机译:HER2mRNa的原位定量测量预测在一组转移性乳腺癌患者中从含曲妥珠单抗的化疗中获益。